|
|
Post by wyattdog on Dec 22, 2021 15:44:36 GMT -5
thanks i almost bought a new monitor:)
|
|
|
|
Post by nxc2 on Dec 22, 2021 21:50:43 GMT -5
They cannot develop powder based product outside of Mannkind facility IMO. I do not think there is any relationship to MNKD. Please provide something factual to support your comment. I have toured the factory in Danbury twice and it is a special and unique place. I also believe the powder must be developed in this facility. I also believe United has some type of clause that protects them because of this uniqueness. |
|
|
|
Post by cedafuntennis on Dec 22, 2021 21:58:17 GMT -5
Please provide something factual to support your comment. I have toured the factory in Danbury twice and it is a special and unique place. I also believe the powder must be developed in this facility. I also believe United has some type of clause that protects them because of this uniqueness. How about producing the prefer in Danbyry like we all agree but shipping it over to Africa for packaging using the single use transport system mentioned? Could that not be a strategy? |
|
|
|
Post by buyitonsale on Dec 22, 2021 23:56:35 GMT -5
They cannot develop powder based product outside of Mannkind facility IMO. I do not think there is any relationship to MNKD. Please provide something factual to support your comment. MNKD would have to license its dry powder technology to be deployed at a third party facility. We do not see any evidence of such collaboration and MNKD is not even mentioned in this PR. MNKD has not licensed anything to Technovax so far, therefore Technovax cannot build or design a facility that has such technology without explicit participation by MNKD. |
|
|
|
Post by hellodolly on Dec 23, 2021 6:21:23 GMT -5
It's so early in the game, let's wait and see if this brings any fruit to MNKD in terms of manufacturing.
|
|
|
|
Post by dh4mizzou on Dec 23, 2021 7:10:02 GMT -5
He wouldn’t, And on another note, am I crazy or is it snowing on Pro-Boards? Sports, Why can't the answer to both questions be yes !! LOL Happy Holidays to all !!!! |
|
|
|
Post by sayhey24 on Dec 23, 2021 19:28:57 GMT -5
Please provide something factual to support your comment. MNKD would have to license its dry powder technology to be deployed at a third party facility. We do not see any evidence of such collaboration and MNKD is not even mentioned in this PR. MNKD has not licensed anything to Technovax so far, therefore Technovax cannot build or design a facility that has such technology without explicit participation by MNKD. Why? That entire DOT ice cream process is staying in Danbury is the theory. If MNKD is making the product in Danbury and bulk shipping the finished powder, what is MNKD licensing? All TechnoVax needs to do is buy the filler finisher from that French company and have them assemble it. Granted, easier said than done but a lot easier than brewing up the powder. I will say, if MNKD is involved this would be a nice Christmas present. |
|
|
|
Post by sweedee79 on Dec 23, 2021 20:02:36 GMT -5
Since when do we get Christmas presents from Mnkd? I'm still waiting.. and waiting and waiting
The only Christmas surprise I remember involved a stock offering.. Mnkd the company got a present from us the shareholder... And nice bonuses too!!
We are due a nice Christmas present... Tho I don't believe we are involved in this technovax deal.. wish we were..
|
|
|
|
Post by falconquest on Dec 27, 2021 9:27:53 GMT -5
He wouldn’t, And on another note, am I crazy or is it snowing on Pro-Boards? For those of us in Northern climes Sports it is easily recognizable.  |
|
|
|
Post by jkendra on Feb 22, 2022 21:25:12 GMT -5
How a Global Network Accelerated the Development of a Virus-Like Particle Vaccine Against Covid-19
By Ute Boronowsky
22/02/2022 - 5 minutes
Vaccines are among the most effective ways to improve and protect human health. Whereas vaccines in Europe and North America are regarded as part of the general medical plan, vaccine supply has always been a pressing issue in African countries. In the current Covid-19 pandemic, the ability to develop and manufacture vaccines in Africa instead of depending on vaccine imports is more critical than ever.
Setting up the logistics and cold chain infrastructure needed for vaccine deployment is expensive and cumbersome, contributing to low vaccination rates in African countries. Enabling local vaccine manufacturing in sufficient quantities and consistent quality could have a significant impact in fighting infectious diseases, including the Covid-19 pandemic.
A partnership between the biotech companies TechnoVax in the US, Merck, and Innovative Biotech in Nigeria aims to empower vaccine development in Africa. Innovative Biotech has already developed vaccines against Ebola and HIV, and with the onset of the Covid-19 pandemic, the company quickly switched to the new target.
“When we first met the Innovative Biotech team, they needed a partner for production and fill and finish services for a Covid-19 vaccine. In the long run, they were looking for more sustainable production activities, including full-service manufacturing in Nigeria,” said Youssef Gaabouri, Head of Sales of Middle East and Africa, BioProcessing at Merck*.
Emerging biotech matchmaking
It turned out that the ideal partner was already part of Merck’s global emerging biotech program, set up to nurture and help advance start-ups to the clinic in an integrated approach. TechnoVax, based in New York, is one of the companies supported in this program and one of the 2019 Emerging Biotech Grant winners. Both Innovative Biotech and TechnoVax use a specific approach to vaccine development known as virus-like particle technology.
Virus-like particle vaccines have become well-established over the last decades, for example, by protecting against the human papillomavirus and hepatitis B virus. They mimic the surface of live viruses, presenting viral surface proteins to the human immune system.
As a result, antibodies and T cells are produced, and memory cells form that can quickly start an immune response in case of an infection. Virus-like particles are not infectious because they do not contain any viral genetic material, making them safe to use.
picture of Naomi Baer, Business Development Consultant for Emerging Biotech at MilliporeSigma North America
“When we connected the two companies, they engaged right away. TechnoVax had already established a virus-like particle-based vaccine development and manufacturing platform, and we were working with them on scaling up their production process,” said Naomi Baer, Business Development Consultant for Emerging Biotech at MilliporeSigma North America.
Now, TechnoVax has become Innovative Biotech’s partner for vaccine development and manufacturing.
Scaling up virus-like particle vaccine manufacturing
Virus-like particle production is usually done in cells, and the removal of cellular components — membranes, proteins, and nucleic acids — is one of the crucial steps of the manufacturing workflow. Optimal filtration, clarification, and purification procedures are first evaluated on a small scale and then scaled up under established Good Manufacturing Practices (GMPs, WHO good manufacturing practices for biological products, Annex 2, Nov 2016).
Merck Lab panorama
“We participated in two on-site trials at TechnoVax in 2019, where we first optimized protocols for cell lysis, nucleic acid removal, and clarification. As a next step, we worked on purification processes including tangential flow filtration and chromatography methods to convert their bench-scale procedures to a GMP-compatible, scalable process, yielding virus-like particle preparations in the quality and quantity required for clinical trials,” Baer explained.
Because most of the optimization was done on-site, the Merck experts could demonstrate the new processes step by step and provide collaboration, training, and support to the TechnoVax team.
“When Covid-19 had us all sheltering in one place, we provided virtual training and online consultations to discuss results and next steps,” Baer added.
Paving the way to vaccine self-sufficiency in African countries
As a result of the combined efforts, TechnoVax was able to develop and produce an effective Covid-19 vaccine in sufficient quantity to start clinical trials in South Africa, Ghana, and Nigeria. TechnoVax plans to achieve emergency use authorization in these countries and from the FDA, EMA, and WHO.
“We engaged our consultants, process validation engineers, and regulatory experts from our BioReliance® team to connect TechnoVax to an FDA consultant, helping to accelerate the regulatory process,” Baer said.
As a next step, virus-like particle production shall be established in Nigeria to produce not only the Covid-19 vaccine but also additional vaccines needed in the region, including Ebola and HIV vaccines.Networking for success
Being part of Merck’s emerging biotech has allowed both TechnoVax and Innovative Biotech to speed up their projects while saving time and money and mitigating risks. In addition, finding the ideal collaboration partner so quickly was a significant stepping stone for their success.
And the two companies are not the only emerging biotechs to benefit from the network. Networking for success
Being part of Merck’s emerging biotech has allowed both TechnoVax and Innovative Biotech to speed up their projects while saving time and money and mitigating risks. In addition, finding the ideal collaboration partner so quickly was a significant stepping stone for their success.
And the two companies are not the only emerging biotechs to benefit from the network.
|
|
|
|
Post by sayhey24 on Feb 23, 2022 8:50:53 GMT -5
This would be a great question for Mike on Thursday about whats happening with Technovax and MNKD.
|
|
|
|
Post by sayhey24 on Feb 23, 2022 9:49:24 GMT -5
|
|
|
|
Post by wmdhunt on Feb 24, 2022 18:04:26 GMT -5
I should think some of MNKD's patents (recent and old) could play a part in all this..
|
|
|
|
Post by jkendra on Jun 20, 2022 19:44:50 GMT -5
Insights from a Global Collaboration Accelerating Vaccine Development with an Optimized VLP Platform
May. 12, 2022
Watch the presentation of this webinar here: bit.ly/3Nbb5ugGet insights and best practices from a multinational team establishing a platform for vaccine production. See how a long-term collaboration on a bench-scale process used to produce a Virus Like Particle (VLP) vaccine for SARS-CoV-2 was successfully converted to a robust GMP-compatible, scalable process. The COVID-19 pandemic further emphasized the need for collaboration in the development of urgently needed vaccines and therapeutics. In this webinar, we take you behind the scenes of our collaboration with Technovax and Innovative Biotech in which a scalable VLP vaccine platform was optimized for use in a production facility in Nigeria in response to the need for local production of SARS-CoV-2 vaccines. The flexibility and robustness of the platform will enable its rapid deployment to support the West African pandemic readiness program. Initial development of the VLP process began in late 2019 and by March 2020, was already adapted for production of a SARS-CoV-2 vaccine. In this webinar, you will learn: • About building a priceless collaborative network with integrated solutions • Virus-Like Particle Vaccines • Process Development Overview and Challenges • Pre-clinical Results and Next Steps Presented by: Jose M. Galarza, PhD, President and Founder of TechnoVax Naomi Baer, Business development consultant, Emerging Biotech, BioProcess division Youssef Gaabouri, Eng. , Associate Director, Head of Sales Middle East & Africa, BioProcess division |
|
|
|
Post by jkendra on Jun 20, 2022 19:59:34 GMT -5
|
|
